{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:21:25Z","timestamp":1783099285855,"version":"3.54.6"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40261-026-01543-1","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:22:10Z","timestamp":1773930130000},"page":"631-640","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-Effectiveness Analysis of Anlotinib Plus Penpulimab Versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma in China"],"prefix":"10.1007","volume":"46","author":[{"given":"JinDi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LongXun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PanFeng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"issue":"3","key":"1543_CR1","first-page":"229","volume":"74","author":"F Ray","year":"2024","unstructured":"Ray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"1543_CR2","doi-asserted-by":"publisher","first-page":"e943","DOI":"10.1016\/S2468-2667(23)00211-6","volume":"8","author":"JL Qi","year":"2023","unstructured":"Qi JL, Li ML, Wang LJ, et al. National and subnational trends in cancer burden in China, 2005\u20132020: an analysis of national mortality surveillance data. Lancet Public Health. 2023;8(12):e943\u201355.","journal-title":"Lancet Public Health."},{"key":"1543_CR3","first-page":"34","volume":"49","author":"X Cheng","year":"2022","unstructured":"Cheng X, Zhang L, Li J, et al. A multi-criteria decision analysisframework for evaluating first-line therapies for unresectable hepatocellular carcinoma. Cancer Ther Rev. 2022;49:34\u201342.","journal-title":"Cancer Ther Rev."},{"issue":"11","key":"1543_CR4","first-page":"879","volume":"29","author":"L An","year":"2020","unstructured":"An L, Zeng HM, Ran XH, et al. Progress on epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. China Cancer. 2020;29(11):879\u201384.","journal-title":"China Cancer"},{"key":"1543_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19:151\u201372.","journal-title":"Nat Rev Clin Oncol"},{"key":"1543_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","volume":"23","author":"T Yau","year":"2022","unstructured":"Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23:77\u201390.","journal-title":"Lancet Oncol"},{"key":"1543_CR7","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","volume":"79","author":"L Rimassa","year":"2023","unstructured":"Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma. J Hepatol. 2023;79:506\u201315.","journal-title":"J Hepatol"},{"key":"1543_CR8","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1007\/s00262-022-03160-1","volume":"71","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, Mislang ARA, Coward J, et al. Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers. Cancer Immunol Immunother. 2022;71:2371\u20139.","journal-title":"Cancer Immunol Immunother"},{"key":"1543_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0664-7","volume":"11","author":"G Shen","year":"2018","unstructured":"Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11:120.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"1543_CR10","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S1470-2045(25)00190-1","volume":"26","author":"J Zhou","year":"2025","unstructured":"Zhou J, Bai L, Luo J, et al. Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial. Lancet Oncol. 2025;26(6):719\u201331.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1543_CR11","first-page":"581","volume":"32","author":"Department of Medical Administration, National Health Commission of the people\u2019s Republic of China","year":"2024","unstructured":"Department of Medical Administration, National Health Commission of the people\u2019s Republic of China. Guideline of diagnosis and and treatment of primary liver cancer. Journal of Multidisciplinary Cancer. 2024;32(7):581\u2013630.","journal-title":"Journal of Multidisciplinary Cancer"},{"issue":"1","key":"1543_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cai2.60","volume":"2","author":"L Zhang","year":"2023","unstructured":"Zhang L, Liu R, Deng T, et al. Advances in medical treatment of advanced hepatobiliary and pancreatic cancer in 2022. Cancer Innov. 2023;2(1):36\u201351.","journal-title":"Cancer Innov."},{"key":"1543_CR13","first-page":"4","volume-title":"China guidelines for pharmacoeconomic evaluation2020","author":"GE Liu","year":"2020","unstructured":"Liu GE. China guidelines for pharmacoeconomic evaluation2020. Beijing: China market Press; 2020. p. 4\u20135 (19, 27-28)."},{"key":"1543_CR14","doi-asserted-by":"publisher","first-page":"1019826","DOI":"10.3389\/fphar.2022.1019826","volume":"13","author":"M You","year":"2022","unstructured":"You M, Chen R, Wu Q, et al. Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer. Front Pharmacol. 2022;13:1019826.","journal-title":"Front Pharmacol"},{"issue":"10","key":"1543_CR15","first-page":"1492","volume":"42","author":"QP Chen","year":"2023","unstructured":"Chen QP, Shao MY, Cui HY, et al. Cost-effectiveness analysis of durvalumab combined with tremelimumab in the first-line treatment of advanced hepatocellular carcinoma. Herald of Medicine. 2023;42(10):1492\u20137.","journal-title":"Herald of Medicine."},{"issue":"22","key":"1543_CR16","first-page":"2761","volume":"32","author":"R Meng","year":"2021","unstructured":"Meng R, Zhou T, Shi FH, et al. Cost-utility analysis of pembrolizuman in the second-line treatment of advanced hepatocellular carcinoma based on two models. China Pharmacv. 2021;32(22):2761\u20136.","journal-title":"China Pharmacv."},{"key":"1543_CR17","doi-asserted-by":"publisher","first-page":"175883592412746","DOI":"10.1177\/17588359241274625","volume":"16","author":"W Liao","year":"2024","unstructured":"Liao W, Xu H, Hutton D, et al. Cost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinoma. Ther Adv Med Oncol. 2024;16:17588359241274624.","journal-title":"Ther Adv Med Oncol."},{"issue":"8","key":"1543_CR18","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2217\/cer-2020-0041","volume":"9","author":"HF Cai","year":"2020","unstructured":"Cai HF, Zhang LF, Li N, et al. Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis. J Comp Eff Res. 2020;9(8):553\u201362.","journal-title":"J Comp Eff Res."},{"issue":"11","key":"1543_CR19","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1016\/j.clinthera.2019.09.008","volume":"41","author":"H Guan","year":"2019","unstructured":"Guan H, Liu G, Xie F, et al. Cost-effectiveness of osimertinib as a second-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer in China. Clin Ther. 2019;41(11):2308-2320.e11.","journal-title":"Clin Ther"},{"issue":"16","key":"1543_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70094","volume":"13","author":"F Wen","year":"2024","unstructured":"Wen F, Huang P, Wu Q, et al. Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: a cost-effectiveness analysis. Cancer Med. 2024;13(16):e70094.","journal-title":"Cancer Med"},{"issue":"10","key":"1543_CR21","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s40261-019-00820-6","volume":"39","author":"J Chen","year":"2019","unstructured":"Chen J, Hu G, Chen Z, et al. Cost-effectiveness analysis of pembrolizumab plus axitinib versus sunitinib in first-line advanced renal cell carcinoma in China. Clin Drug Investig. 2019;39(10):931\u20138.","journal-title":"Clin Drug Investig"},{"key":"1543_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.790225","volume":"10","author":"M Zhan","year":"2022","unstructured":"Zhan M, Xu T, Zheng HR, et al. Cost-effectiveness analysis of pembrolizumab in patients with advanced esophageal cancer based on the KEYNOTE-181 study[J]. Front Public Health. 2022;10:790225.","journal-title":"Front Public Health"},{"key":"1543_CR23","unstructured":"Yao ZH. The big data service platform for china\u2019s health industry: information query of drug bid winning (2024). Available at: https:\/\/www.yaozh.com\/. Accessed 20 July 2025."},{"issue":"11","key":"1543_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13014-016-0644-4","volume":"18","author":"HW Leung","year":"2016","unstructured":"Leung HW, Liu CF, Chan AL. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma. Radiat Oncol. 2016;18(11):69.","journal-title":"Radiat Oncol"},{"key":"1543_CR25","unstructured":"National Bureau of Statistics of China. National Data: Exchange Rate [DB\/OL]. [2025-07-20]. https:\/\/data.stats.gov.cn\/search.htm?s=C01. Accessed 20 Jul 2025."},{"issue":"13","key":"1543_CR26","doi-asserted-by":"publisher","first-page":"1264417","DOI":"10.3389\/fonc.2023.1264417","volume":"8","author":"CY Tseng","year":"2023","unstructured":"Tseng CY, Tsai YW, Shiu MN. Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first line treatment for Chinese subpopulation with unresectable hepatocellular carcinoma. Front Oncol. 2023;8(13):1264417.","journal-title":"Front Oncol"},{"issue":"5","key":"1543_CR27","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1007\/s12325-022-02079-4","volume":"39","author":"T Zhou","year":"2022","unstructured":"Zhou T, Cao Y, Wang X, et al. Economic evaluation of Sintilimab plus Bevacizumab versus Sorafenib as a first-line treatment for unresectable hepatocellular carcinoma. Adv Ther. 2022;39(5):2165\u201377.","journal-title":"Adv Ther"},{"issue":"13","key":"1543_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.778505","volume":"9","author":"Y Peng","year":"2022","unstructured":"Peng Y, Zeng X, Peng L, et al. Sintilimab plus bevacizumab biosimilar versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis. Front Pharmacol. 2022;9(13):778505.","journal-title":"Front Pharmacol"},{"issue":"13","key":"1543_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.891008","volume":"1","author":"L Li","year":"2022","unstructured":"Li L, Yang S, Chen Y, et al. Immune checkpoint inhibitors plus an anti-VEGF antibody as the first-line treatment for unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis. Front Pharmacol. 2022;1(13):891008.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1543_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0295090","volume":"19","author":"Q Chen","year":"2024","unstructured":"Chen Q, Sun Q, Zhang J, et al. Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma. PLoS ONE. 2024;19(3):e0295090.","journal-title":"PLoS ONE"},{"issue":"13","key":"1543_CR31","doi-asserted-by":"publisher","first-page":"1620663","DOI":"10.3389\/fpubh.2025.1620663","volume":"31","author":"L Tang","year":"2025","unstructured":"Tang L, Zhu L, Zhan S, et al. Cost-effectiveness analysis of sugemalimab combined with chemotherapy as first-line treatment for advanced gastric cancer. Front Public Health. 2025;31(13):1620663.","journal-title":"Front Public Health"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01543-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01543-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01543-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:48:28Z","timestamp":1779806908000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01543-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1543"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01543-1","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable. This manuscript presents a model-based cost-effectiveness analysis. As it is a secondary analysis of data derived from previously published clinical trials and uses no original data from human subjects, ethics committee approval was not required and was not sought.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The datasets analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Conceptualization, data curation and formal analysis: Lian Tang and LongXun Zhu; Writing\u2014original draft and writing\u2014review & editing: JinDi Liu, PanFeng Feng and Yong Chen. All authors read and approved the final manuscript and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}